{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:39:14Z","timestamp":1791261554806,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"DOI":"10.1007\/s11906-026-01381-8","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:14:10Z","timestamp":1784607250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Toward Precision Aspirin Prophylaxis: Optimal Aspirin Dosing For Prevention of Preeclampsia"],"prefix":"10.1007","volume":"28","author":[{"given":"Priyanka","family":"Gaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Malha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrin","family":"Khander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"6","key":"1381_CR1","doi-asserted-by":"publisher","first-page":"E237","DOI":"10.1097\/AOG.0000000000003891","volume":"135","author":"J Espinoza","year":"2020","unstructured":"Espinoza J, Vidaeff A, Pettker CM, Simhan H. Gestational hypertension and preeclampsia. Obstet Gynecol. 2020;135(6):E237\u201360.","journal-title":"Obstet Gynecol"},{"issue":"7","key":"1381_CR2","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1161\/CIRCRESAHA.118.313276","volume":"124","author":"S Rana","year":"2019","unstructured":"Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124(7):1094\u2013112.","journal-title":"Circ Res"},{"issue":"1","key":"1381_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/HYPERTENSIONAHA.117.10803","volume":"72","author":"MA Brown","year":"2018","unstructured":"Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(1):24\u201343.","journal-title":"Hypertension"},{"key":"1381_CR4","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.placenta.2013.12.008","volume":"35","author":"CW Redman","year":"2014","unstructured":"Redman CW, Sargent IL, Staff AC. IFPA senior award lecture: making sense of pre-eclampsia\u2013two placental causes of preeclampsia? Placenta. 2014;35:S20\u20135.","journal-title":"Placenta"},{"key":"1381_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jri.2019.07.004","volume":"134","author":"AC Staff","year":"2019","unstructured":"Staff AC. The two-stage placental model of preeclampsia: an update. J Reprod Immunol. 2019;134:1\u20130.","journal-title":"J Reprod Immunol"},{"key":"1381_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l2381","author":"GJ Burton","year":"2019","unstructured":"Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l2381.","journal-title":"BMJ"},{"issue":"2","key":"1381_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/GRF.0000000000000857","volume":"67","author":"AA Sanusi","year":"2024","unstructured":"Sanusi AA, Sinkey RG, Tita AT. Clinical trials that have changed obstetric practice: the Chronic Hypertension and Pregnancy (CHAP) trial. Clin Obstet Gynecol. 2024;67(2):411\u20137.","journal-title":"Clin Obstet Gynecol"},{"issue":"1","key":"1381_CR8","doi-asserted-by":"publisher","first-page":"39S","DOI":"10.1378\/chest.119.1_suppl.39S","volume":"119","author":"C Patrono","year":"2001","unstructured":"Patrono C, Coller B, Dalen JE, Gerald GA, Fuster V, Gent M, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119(1):39S-63S.","journal-title":"Chest"},{"key":"1381_CR9","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists. Low-dose aspirin use during pregnancy. ACOG Committee Opinion No. 743. Obstet Gynecol. 2018;132(01):254\u20136.","DOI":"10.1097\/AOG.0000000000002709"},{"issue":"2","key":"1381_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/bcpt.13308","volume":"127","author":"KM Mirabito Colafella","year":"2020","unstructured":"Mirabito Colafella KM, Neuman RI, Visser W, Danser AJ, Versmissen J. Aspirin for the prevention and treatment of pre\u2010eclampsia: a matter of COX\u20101 and\/or COX\u20102 inhibition? Basic Clin Pharmacol Toxicol. 2020;127(2):132\u201341.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"1381_CR11","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.placenta.2015.01.004","volume":"36","author":"C Li","year":"2015","unstructured":"Li C, Raikwar NS, Santillan MK, Santillan DA, Thomas CP. Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1. Placenta. 2015;36(4):446\u201353.","journal-title":"Placenta"},{"issue":"12","key":"1381_CR12","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1097\/HJH.0000000000002185","volume":"37","author":"MT Su","year":"2019","unstructured":"Su MT, Wang CY, Tsai PY, Chen TY, Tsai HL, Kuo PL. Aspirin enhances trophoblast invasion and represses soluble fms-like tyrosine kinase 1 production: a putative mechanism for preventing preeclampsia. J Hypertens. 2019;37(12):2461\u20139.","journal-title":"J Hypertens"},{"issue":"7","key":"1381_CR13","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/pd.4403","volume":"34","author":"E Bujold","year":"2014","unstructured":"Bujold E, Roberge S, Nicolaides KH. Low\u2010dose aspirin for prevention of adverse outcomes related to abnormal placentation. Prenat Diagn. 2014;34(7):642\u20138.","journal-title":"Prenat Diagn"},{"issue":"5","key":"1381_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pd.5645","volume":"40","author":"L Loussert","year":"2020","unstructured":"Loussert L, Vidal F, Parant O, Hamdi SM, Vayssiere C, Guerby P. Aspirin for prevention of preeclampsia and fetal growth restriction. Prenat Diagn. 2020;40(5):519\u201327.","journal-title":"Prenat Diagn"},{"key":"1381_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.mehy.2017.07.033","volume":"108","author":"JM Santos","year":"2017","unstructured":"Santos JM, Park JA, Joiakim A, Putt DA, Taylor RN, Kim H. The role of soluble epoxide hydrolase in preeclampsia. Med Hypotheses. 2017;108:81\u20135.","journal-title":"Med Hypotheses"},{"issue":"12","key":"1381_CR16","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.2165\/00003088-200342120-00004","volume":"42","author":"C Cerletti","year":"2003","unstructured":"Cerletti C, Dell\u2019Elba G, Manarini S, Pecce R, Di Castelnuovo A, Scorpiglione N, et al. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet. 2003;42(12):1059\u201370.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1381_CR17","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ajog.2024.10.023","volume":"232","author":"R Vinogradov","year":"2025","unstructured":"Vinogradov R, Kavanagh ON, Palmer J, Murphy P, Curtis E, Kamali F, et al. A randomized crossover design study comparing the pharmacokinetics and pharmacodynamics of 2 single doses of oral aspirin (75 mg v 150 mg) in pregnant women at risk of preeclampsia: implications on assessing aspirin response and patient adherence to therapy. Am J Obstet Gynecol. 2025;232(5):474-e1.","journal-title":"Am J Obstet Gynecol"},{"key":"1381_CR18","doi-asserted-by":"crossref","unstructured":"Combs CA, Kumar NR, Morgan JL, Safety SP, Society for Maternal-Fetal Medicine (SMFM, Quality Committee. Society for Maternal-Fetal Medicine Special Statement: Prophylactic low-dose aspirin for preeclampsia prevention\u2014quality metric and opportunities for quality improvement. American journal of obstetrics and gynecology. 2023;229(2):B2-9.","DOI":"10.1016\/j.ajog.2023.04.039"},{"key":"1381_CR19","doi-asserted-by":"crossref","unstructured":"LeFevre ML, US Preventive Services Task Force*. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: US Preventive Services Task Force recommendation statement. Annals of internal medicine. 2014;161(11):819-26.","DOI":"10.7326\/M14-1884"},{"key":"1381_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2025.10.028","author":"N Mans-Gallart","year":"2025","unstructured":"Mans-Gallart N, Carlh\u00e4ll S, Hildebrand E, Axelsson D, Lilliecreutz C. Early risk assessment and aspirin prophylaxis did not reduce preterm preeclampsia in Sweden: a population-based study. Am J Obstet Gynecol. 2025. https:\/\/doi.org\/10.1016\/j.ajog.2025.10.028.","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"1381_CR21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMoa1704559","volume":"377","author":"DL Rolnik","year":"2017","unstructured":"Rolnik DL, Wright D, Poon LC, O\u2019Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613\u201322.","journal-title":"N Engl J Med"},{"issue":"2","key":"1381_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ajog.2016.09.076","volume":"216","author":"S Roberge","year":"2017","unstructured":"Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216(2):110\u201320.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"1381_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247782","volume":"16","author":"R Van Doorn","year":"2021","unstructured":"Van Doorn R, Mukhtarova N, Flyke IP, Lasarev M, Kim K, Hennekens CH, et al. Dose of aspirin to prevent preterm preeclampsia in women with moderate or high-risk factors: a systematic review and meta-analysis. PLoS ONE. 2021;16(3):e0247782.","journal-title":"PLoS ONE"},{"issue":"5","key":"1381_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/jch.14821","volume":"26","author":"X Hu","year":"2024","unstructured":"Hu X, Chen D, Wang H, Lv Y, Wang Y, Gao X, et al. The optimal dosage of aspirin for preventing preeclampsia in high\u2010risk pregnant women: a network meta\u2010analysis of 23 randomized controlled trials. J Clin Hypertens. 2024;26(5):455\u201364.","journal-title":"J Clin Hypertens"},{"key":"1381_CR25","doi-asserted-by":"publisher","unstructured":"Ghesquiere L, Guerby P, Marchant I, Kumar N, Zare M, Foisy MA, Roberge S, Bujold E. Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2023;5(7):101000. https:\/\/doi.org\/10.1016\/j.ajogmf.2023.101000","DOI":"10.1016\/j.ajogmf.2023.101000"},{"issue":"2","key":"1381_CR26","doi-asserted-by":"publisher","first-page":"e2457828","DOI":"10.1001\/jamanetworkopen.2024.57828","volume":"8","author":"E Kupka","year":"2025","unstructured":"Kupka E, Hesselman S, Gunnarsd\u00f3ttir J, Wikstr\u00f6m AK, Cluver C, Tong S, et al. Prophylactic aspirin dose and preeclampsia. JAMA Netw Open. 2025;8(2):e2457828.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"1381_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-096779","volume":"15","author":"A Khander","year":"2025","unstructured":"Khander A, Matthews K, Christos P, Thomas C, Alam T, Alcus C, et al. Randomised controlled trial comparing low doses of aspirin in the prevention of pre-eclampsia (ASAPP): a study protocol. BMJ Open. 2025;15(7):e096779.","journal-title":"BMJ Open"},{"key":"1381_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2025.10.032","author":"E Bujold","year":"2025","unstructured":"Bujold E, Rolnik DL, Poon L, Syngelaki A, Wright D, Nicolaides KH. The effect of aspirin on the risk of preeclampsia based on the Fetal Medicine Foundation first trimester risk. Am J Obstet Gynecol. 2025. https:\/\/doi.org\/10.1016\/j.ajog.2025.10.032.","journal-title":"Am J Obstet Gynecol"},{"key":"1381_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2026.03.025","author":"N Mans-Gallart","year":"2026","unstructured":"Mans-Gallart N, Axelsson D, Lilliecreutz C. Response to concerns about early risk assessment and aspirin prophylaxis in Sweden (reply to letter to the editor). Am J Obstet Gynecol. 2026. https:\/\/doi.org\/10.1016\/j.ajog.2026.03.025.","journal-title":"Am J Obstet Gynecol"},{"issue":"21","key":"1381_CR30","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, Despr\u00e9s JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984-1010.","journal-title":"Circulation"},{"issue":"3","key":"1381_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ajog.2024.06.038","volume":"232","author":"FH Amro","year":"2025","unstructured":"Amro FH, Blackwell SC, Pedroza C, Backley S, Bitar G, Daye N, et al. Aspirin 162 mg vs 81 mg for preeclampsia prophylaxis in high-risk obese individuals: a comparative effectiveness open-label randomized trial (ASPREO). Am J Obstet Gynecol. 2025;232(3):315-e1.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"1381_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2022.100803","volume":"5","author":"F D'Antonio","year":"2023","unstructured":"D\u2019Antonio F, Khalil A, Rizzo G, Fichera A, Herrera M, Buca D, et al. Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2023;5(2):100803.","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"3","key":"1381_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ajog.2020.03.005","volume":"223","author":"E Kalafat","year":"2020","unstructured":"Kalafat E, Shirazi A, Thilaganathan B, Khalil A. The role of aspirin in prevention of preeclampsia in twin pregnancies: does the dose matter? Am J Obstet Gynecol. 2020;223(3):457\u20138.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"1381_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ajog.2024.12.030","volume":"233","author":"P Zorzato","year":"2025","unstructured":"Zorzato P, Torcia E, Carlin A, Familiari A, Cosmi E, Visentin S, et al. Comparison of two aspirin doses for the prophylaxis of pre-eclampsia in twin pregnancy: a multicenter retrospective study with propensity score matching. Am J Obstet Gynecol. 2025;233(1):55-e1.","journal-title":"Am J Obstet Gynecol"},{"key":"1381_CR35","unstructured":"Fundaci\u00f3n para la Formaci\u00f3n e Investigaci\u00f3n Sanitarias de la Regi\u00f3n de Murcia. Use of aspirin for the prevention of preeclampsia in twin pregnancies (ASPRE-T). ISRCTN Registry. 2022. ISRCTN86684235. Available from: ISRCTN Registry Record."},{"issue":"3","key":"1381_CR36","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ajog.2023.12.028","volume":"231","author":"RC Boelig","year":"2024","unstructured":"Boelig RC, Kaushal G, Rochani A, McKenzie SE, Kraft WK. Aspirin pharmacokinetics and pharmacodynamics through gestation. Am J Obstet Gynecol. 2024;231(3):344-e1.","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"1381_CR37","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ajog.2017.07.038","volume":"217","author":"LC Poon","year":"2017","unstructured":"Poon LC, Wright D, Rolnik DL, Syngelaki A, Delgado JL, Tsokaki T, et al. Aspirin for evidence-based preeclampsia prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. Am J Obstet Gynecol. 2017;217(5):585-e1.","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"1381_CR38","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/1471-0528.18095","volume":"132","author":"B Atkins","year":"2025","unstructured":"Atkins B, Siassakos D. Optimising aspirin use for pre\u2010eclampsia prevention: the critical role of dose, timing and adherence. BJOG Int J Obstet Gynaecol. 2025;132(5):547.","journal-title":"BJOG Int J Obstet Gynaecol"},{"issue":"6","key":"1381_CR39","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00404-021-06349-4","volume":"305","author":"KC Yip","year":"2022","unstructured":"Yip KC, Luo Z, Huang X, Lee W, Li L, Dai C, et al. The role of aspirin dose and initiation time in the prevention of preeclampsia and corresponding complications: a meta-analysis of RCTs. Arch Gynecol Obstet. 2022;305(6):1465\u201379.","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"1381_CR40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jacc.2018.10.075","volume":"73","author":"DG Halpern","year":"2019","unstructured":"Halpern DG, Weinberg CR, Pinnelas R, Mehta-Lee S, Economy KE, Valente AM. Use of medication for cardiovascular disease during pregnancy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(4):457\u201376.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1381_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14072134","volume":"14","author":"B Komor\u00f3czy","year":"2025","unstructured":"Komor\u00f3czy B, V\u00e1ncsa S, V\u00e1radi A, Hegyi P, V\u00e1g\u00e1si V, Barad\u00e1cs I, et al. Optimal aspirin dosage for the prevention of preeclampsia and other adverse pregnancy outcomes: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2025;14(7):2134.","journal-title":"J Clin Med"},{"issue":"22","key":"1381_CR42","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1056\/NEJMra052717","volume":"353","author":"C Patrono","year":"2005","unstructured":"Patrono C, Garc\u00eda Rodr\u00edguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373\u201383.","journal-title":"N Engl J Med"},{"issue":"4","key":"1381_CR43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3949\/ccjm.92a.24125","volume":"92","author":"SL Cohn","year":"2025","unstructured":"Cohn SL. 2024 ACC\/AHA guideline on perioperative cardiovascular management before noncardiac surgery: what\u2019s new? Clevel Clin J Med. 2025;92(4):213\u20139.","journal-title":"Clevel Clin J Med"},{"issue":"5","key":"1381_CR44","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/SLA.0b013e318250504e","volume":"255","author":"NS Gerstein","year":"2012","unstructured":"Gerstein NS, Schulman PM, Gerstein WH, Petersen TR, Tawil I. Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome. Ann Surg. 2012;255(5):811\u20139.","journal-title":"Ann Surg"},{"key":"1381_CR45","unstructured":"Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy [Internet]. Bethesda (MD): National Library of Medicine (US). ClinicalTrials.gov Identifier: NCT06468202; 2024 [cited 2026 Jun 5]. Available from: ClinicalTrials.gov."},{"key":"1381_CR46","unstructured":"Maternal-Fetal Medicine Units Network. Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial (ADEPT) [Internet]. ClinicalTrials.gov Identifier: NCT06980025; [cited 2026 Jun 5]. Available from: ClinicalTrials.gov ADEPT Record."},{"issue":"7","key":"1381_CR47","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jama.2023.0691","volume":"329","author":"M Mendoza","year":"2023","unstructured":"Mendoza M, Bonacina E, Garcia-Manau P, L\u00f3pez M, Caami\u00f1a S, Vives \u00c0, et al. Aspirin discontinuation at 24 to 28 weeks\u2019 gestation in pregnancies at high risk of preterm preeclampsia: a randomized clinical trial. JAMA. 2023;329(7):542\u201350.","journal-title":"JAMA"},{"issue":"4","key":"1381_CR48","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1161\/01.HYP.34.4.1016","volume":"34","author":"RC Hermida","year":"1999","unstructured":"Hermida RC, Ayala DE, Fern\u00e1ndez JR, Moj\u00f3n A, Alonso I, Silva I, et al. Administration time\u2013dependent effects of aspirin in women at differing risk for preeclampsia. Hypertension. 1999;34(4):1016\u201323.","journal-title":"Hypertension"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-026-01381-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-026-01381-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-026-01381-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:14:11Z","timestamp":1784607251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-026-01381-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1381"],"URL":"https:\/\/doi.org\/10.1007\/s11906-026-01381-8","relation":{},"ISSN":["1534-3111"],"issn-type":[{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"7 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","label":"Human and Animal Rights","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}}],"article-number":"31"}}